Senior Consultant, Department of Cardiology, Medanta Moolchand Heart Institute, Delhi.
Professor and Head, Department of Cardiology, Dayanand Medical College & Hospital (DMCH), Ludhiana, Punjab; Corresponding Author.
J Assoc Physicians India. 2023 Mar;71(3):11-12. doi: 10.5005/japi-11001-0214.
Iron deficiency (ID) with or without anemia is frequently observed in patients with heart failure (HF). Uncorrected ID is associated with higher hospitalization and mortality in patients with acute HF (AHF) and chronic HF (CHF). Hence, in addition to chronic renal insufficiency, anemia, and diabetes, ID appears as a novel comorbidity and a treatment target of CHF. Intravenous (IV) ferric carboxymaltose (FCM) reduces the hospitalization risk due to HF worsening and improves functional capacity and quality of life (QOL) in HF patients. The current consensus document provides criteria, an expert opinion on the diagnosis of ID in HF, patient profiles for IV FCM, and correct administration and monitoring of such patients.
缺铁（ID）伴或不伴贫血在心力衰竭（HF）患者中很常见。未经纠正的 ID 与急性心力衰竭（AHF）和慢性心力衰竭（CHF）患者的住院率和死亡率升高有关。因此，除了慢性肾功能不全、贫血和糖尿病之外，ID 似乎成为 CHF 的一种新的合并症和治疗靶点。静脉注射（IV）羧基麦芽糖铁（FCM）降低了 HF 恶化导致的住院风险，并改善了 HF 患者的功能能力和生活质量（QOL）。目前的共识文件提供了 HF 患者 ID 诊断的标准、专家意见、IV FCM 的患者特征以及对这些患者的正确管理和监测。
